Small biotech Inipharm lands $35M to take new NASH approach, diverging from RNAi competitors
A year after Cirius Therapeutics’ lead NASH drug flopped in a large Phase IIb trial, the biotech’s chief business and financial officer Brian Farmer is leading another stab at the Holy Grail of liver disease through the small Seattle-based biotech Inipharm.
The Frazier Healthcare portfolio company landed a $35 million Series A, bringing its total raise to about $40 million. Farmer says he’ll use the funding to push the lead program — which targets the HSD17B13 gene —through IND filing and into the clinic. And while the CEO and co-founder declined to offer a specific timeline, he said “next year is kind of a very important year for us,” adding that they’ll be talking more about data and plans for human trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.